Source: Science Commons Blog 

Over at the FasterCures blog, Margaret Anderson, the organization’s Chief Operating Officer, has a post on the recent Institute of Medicine forum: Breakthrough Business Models: Drug Development for Rare and Neglected Diseases and Individualized Therapies. Anderson, who moderated a panel at the forum, observes that while the Michael J. Fox Foundation is often cited as an example of what’s working well, surprisingly few research foundations embrace its innovative approaches. Key among them: pursuing collaborations with for-profit companies.

Read full posting

Source: David Bollier, Blog

“For those of us who don’t venture into the laboratories of science, it’s difficult to appreciate how fragmented, proprietary, and inefficient drug and disease research truly is. At a time when the Internet is making it easier than ever to share and collaborate, some of the most well-funded, high-tech scientific projects today still operate in their own isolated silos. They are effectively cut off from vast quantities of potentially useful research, scientific literature, emerging ideas, and potential collaborators.

“As Marty Tenenbaum and John Wilbanks put it, the current system is plagued by ‘dibilitating delays, legal wrangling, and technical incompatibilities that frustrate scientific collaboration….'”

Read full posting